Aripiprazole Tablet
Product Images NDC 50090-6563

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-6563). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (Image Fig1 Effectofofotherdrug Arip)

A pharmacokinetic chart illustrating the effect of various drugs on aripiprazole fold change and 90% confidence intervals. The graph displays change relative to a reference without interacting drug, comparing inhibitors, inducers, gastric acid blockers, and other drugs by their area under the curve (AUC) and maximum concentration (Cmax) effects on aripiprazole.*

FDA Label Image

Image 2 (Image Fig2 Effectofotherdrug Dehydroaripip)

A pharmacokinetic chart titled 'The Effect of Other Drugs on Dehydro-Aripiprazole Pharmacokinetics' showing fold change and 90% confidence intervals for AUC and Cmax of dehydro-aripiprazole when combined with various inhibitors, inducers, and other drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam relative to a reference without interacting drugs.*

FDA Label Image

Image 3 (Image Fig3 Effectofarip Otherdrug)

A pharmacokinetic chart illustrating the effect of aripiprazole on the pharmacokinetics (PK) of various other drugs, shown as fold change relative to reference without interacting drug. The horizontal axis represents fold change (0.5 to 3.0), while the vertical list includes drugs such as dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine and escitalopram. The chart includes data points for parameters like AUC and Cmax with 90% confidence intervals for each drug.*

FDA Label Image

Image 4 (Image Fig4 Effectofintrinsicfactor Arip)

A pharmacokinetic chart illustrating the effect of intrinsic factors on aripiprazole, displaying fold change and 90% confidence intervals for various special populations. Factors include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with data points for AUC and Cmax presented relative to reference values.*

FDA Label Image

Image 5 (Image Fig5 Effectofintrinsicfactor Dehydroarip)

A pharmacokinetic chart titled 'The Effect of Intrinsic Factors on Dehydro-Aripiprazole Pharmacokinetics' showing fold change and 90% confidence intervals of AUC and Cmax for variables including CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and renal impairment. The x-axis represents change relative to reference from 0 to 3.*

FDA Label Image

Fig 6 (Image Fig6 Schizophreniastudy 5)

A Kaplan-Meier curve showing the cumulative proportion of patients with relapse in a schizophrenia study over 182 days from randomization. The graph compares relapse proportions for aripiprazole (solid blue line) and placebo (dashed red line), with the y-axis representing proportion with relapse and the x-axis representing days. Numbers at risk for both groups are listed below the x-axis.*

FDA Label Image

7 (Image Fig7 Bipolarstudy 7)

Kaplan-Meier estimation graph showing the cumulative proportion of patients with relapse over time in a bipolar study comparing aripiprazole and placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Lines for aripiprazole and placebo treatments are displayed alongside numbers of subjects at risk over time.*

FDA Label Image

8 (Image Fig8 Bipolarstudy 8)

A Kaplan-Meier curve chart showing the cumulative proportion of patients with relapse to any mood event over 364 days. The graph compares relapse rates between aripiprazole and placebo groups in Bipolar Study 8. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. A table below the graph lists the number of subjects at risk over time for both groups.*

FDA Label Image

9 (Image Fig9 Tourettesdisorderstudy1)

Line graph showing least square means of change from baseline in YGTSS Total Tic Score over 8 weeks of treatment in a Tourette's Disorder study. The graph compares three groups: ARIP-LOW, ARIP-HIGH, and Placebo, charting their tic score changes from baseline across weeks.*

FDA Label Image

Image (Image Logo Medguide)

FDA Label Image

Logo (Image Logo Pi)

FDA Label Image

Description Image (Image Structure)

Chemical structure of aripiprazole showing its molecular framework with distinct functional groups including chlorophenyl, piperazine, and quinolinone moieties.*

FDA Label Image

Label Image (Lbl500906563)

Aripiprazole 5 mg oral tablets label from A-S Medication Solutions. This label shows the product's NDC (50090-6563-0), dosage strength of 5 mg per tablet, storage instructions (store at 68 to 77 degrees Fahrenheit), and package size of 30 tablets. The label includes a QR code and distributor location in Libertyville, IL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.